Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. It develops Fycompa, an antiepileptic drug in the neurology area that is approved as an adjunctive therapy for partial-onset seizures in Japan, the United States, Europe, and Asia. The company is also approved for use as monotherapy for the treatment of partial onset seizures in the United States; and as an adjunctive therapy for primary generalized tonic-clonic seizures in Japan, the United States, Europe, and Asia. It also offers Aricept for the treatment of Alzheimer's disease/dementia with Lewy bodies worldwide; and BELVIQ, an antiobesity agent in the United States. In addition, it develops Halaven, an anticancer agent in the oncology area for use in the treatment of breast cancer in approximately 65 countries and also for use in the treatment of malignant soft tissue sarcoma in 50 countries; and Lenvima, an anticancer agent for use in the treatment of thyroid cancer in Japan, the United States, Europe, and Asia. Further, the company has been approved as combination therapy with everolimus for use in the treatment of renal cell carcinoma in the United States and Europe. It has strategic collaboration with Merck & Co., Inc. for Lenvima in the oncology and dementia fields; and with Ono Pharmaceutical Co., Ltd. for Lenvima and Opdivo combination therapy for the treatment of hepatocellular carcinoma, as well as Collaboration Agreement with Ono Pharmaceutical Co., Ltd. to develop a therapy for treatment of hepatocellular carcinoma. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.
Read More
